This webinar is a joint presentation of Taconic and LifeCanvas Technologies.
Transgenic mouse models are crucial to understanding the mechanisms of neurodegenerative disorders like Alzheimer’s disease and evaluating efficacious therapies. With this goal in mind, Taconic Biosciences has teamed up with LifeCanvas Technologies to characterize pathological markers of Alzheimer’s disease and investigate how the disease progresses using advanced 3D histological technology in two Taconic mouse models: APPSWE and ARTE10 (APP-PS1).
Alzheimer’s disease is a multifaceted progressive neurodegenerative disease with many underlying mechanisms. Each preclinical model typically allows for the investigation of a particular hypothesis, such as an assessment of tangles or plaques. Taconic’s APPSWE and ARTE10 (APP-PS1) models, which are commonly used for preclinical therapeutic efficacy studies in Alzheimer’s disease, both express high concentrations of the β-amyloid precursor protein, resulting in amyloid plaque depositions and reactive glia.
In this webinar, Dr. Moriah Jacobson and Dr. Adam Hall will discuss how the combination of disease-specific mouse models and advanced imaging technology can help researchers gain improved insight into Alzheimer’s disease. They will provide an overview of the current available characterization and imaging data of these two mouse models, as well as reveal how 3D imaging technology facilitates the analysis of distribution and density of plaques present in each model at different ages, which can improve the evaluation of potential therapeutics.
Attend this webinar to:
Adam C. Hall, PhD
HEAD OF SCIENTIFIC AFFAIRS | LIFECANVAS TECHNOLOGIES
Adam C. Hall, PhD is Head of Scientific Affairs at LifeCanvas Technologies where he coordinates 3D tissue clearing and imaging contract research projects related to molecular phenotyping neuroanatomy, neuropharmacology, developmental neurobiology, and neurodegenerative disorders. Adam received his PhD in Biochemistry from Imperial College at the University of London, and his Masters in Pharmacology from Gonville & Caius College at the University of Cambridge, UK. In his postdoctoral research at Imperial College and beyond he explored the neuropharmacology and neurotoxicology of anoretic, anesthetic, and anxiolytic agents.
Moriah L. Jacobson, PhD
FIELD APPLICATIONS SCIENTIST | TACONIC BIOSCIENCES
Moriah L. Jacobson, PhD is a Field Application Scientist II with Taconic Biosciences since October 2020. She has deep expertise in the development, execution, and review of translational rodent studies. She obtained her Ph.D. in Integrative Neuroscience from Stony Brook University, where she discovered novel biomarkers for several models of chronic stress and chemotherapy-induced cognitive impairment and peripheral neuropathy. She then completed her postdoctoral research at Uniformed Services University where she studied novel rapid acting antidepressant drugs targeting kappa opioid receptors.